| A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity | Phase 2 Study of the Assessment of the Insulin Sensitizing Activity of Fenretinide in Subjects With Insulin Resistance With BMI >30Kg/m2, and Liver Inflammation Related to Non-alcoholic Fatty Liver | NCT00546455 |
| Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | A Phase I-II Trial of Fenretinide (4-HPR) + Rituximab in Patients With B-cell Lymphoma | NCT00288067 |
| ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer | A Phase 1a/1b Trial in Relapsed/Refractory Small Cell Lung Cancer to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion | NCT06922539 |
| N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma | Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder in Patients With Recurrent or Resistant Neuroblastoma | NCT00295919 |
| Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Malignant Solid Tumors | NCT00387504 |
| Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration | A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration | NCT00429936 |
| Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients | Comparison Efficacy of Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients: Double-blind Placebo Controlled Study | NCT00534898 |
| Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma | Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas | NCT00589381 |
| N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma | A Phase I Study of Intravenous (Emulsion) Fenretinide in Children With Recurrent or Resistant Neuroblastoma | NCT00646230 |
| Breast cancer prevention with fenretinide in young women at genetic and familial risk. A phase III randomized clinical trial - ND | Breast cancer prevention with fenretinide in young women at genetic and familial risk. A phase III randomized clinical trial - ND | EUCTR2009-010260-41-IT |
| Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | "A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children With Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND #70,058""" | NCT01187810 |
| Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma | NCT01535157 |
| The effects of fenretinide on insulin sensitivity | A randomized double blind placebo controlled study on the effects of fenretinide Lym-X-Sorb on insulin sensitivity in obese insulin resistant subjects - The effects of fenretinide on insulin sensitivity | EUCTR2011-006165-18-NL |
| Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies | Phase I Trial of Intravenous Fenretinide (4-HPR) Plus Intravenous Safingol for Patients With Relapsed Malignancies | NCT01553071 |
| Het effect van fenretinide op insulinegevoeligheid. | A randomized double blind placebo controlled study on the effects of fenretinide Lym-X-Sorb on insulin sensitivity in obese insulin resistant subjects. | NL-OMON25232 |
| Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma | Expanded Access Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder Plus Ketoconazole in Patients With Recurrent or Resistant Neuroblastoma (IND#68,254) | NCT02075177 |
| Safety Study of Fenretinide in Adult Patients With Cystic Fibrosis | An Adaptive Phase I Intra-patient Dose Escalation Study of Fenretinide in Adult Cystic Fibrosis Patients | NCT02141958 |
| Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas | Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL) | NCT02495415 |
| Phase 1 Trial of ST-001 NanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 Mg/mL) for Intravenous Infusion | NCT04234048 |
| Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer | Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies | NCT00104923 |
| Fenretinide and Lonafarnib in Treating Patients With Advanced or Recurrent Head and Neck Cancer | A Phase IB Randomized Translational Study of Fenretinide (4-HPR) in Combination With SCH66336, a Farnesyl Transferase Inhibitor, in Patients With Advanced or Recurrent Head and Neck Cancer | NCT00103090 |
| A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers | A Phase 1a, Randomized, Double-blind Placebo-controlled Study to Evaluate Safety and Tolerability and to Characterize the Pharmacokinetic Profile of Single Ascending Doses of Fenretinide Oral Capsules in Healthy Adult Volunteers | NCT06181760 |
| Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries | A Multicenter Randomized Double-Blinded Trial for Chemoprevention of Ovarian Cancer: Modulation of Biomarkers and Spectral Properties Using Contrast Enhanced Ultrasound in High-Risk Women Using Fenretinide (4-HPR) | NCT00098800 |
| Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer | PHASE III DOUBLE-BLIND, PLACEBO-CONTROLLED, PROSPECTIVE RANDOMIZED COMPARISON OF ADJUVANT THERAPY WITH TAMOXIFEN VS. TAMOXIFEN AND FENRETINIDE IN POSTMENOPAUSAL WOMEN WITH INVOLVED AXILLARY LYMPH NODES AND POSITIVE RECEPTORS | NCT00002646 |
| Fenretinide in Treating Patients With Cervical Neoplasia | A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3 | NCT00003075 |
| Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer | Randomized Chemoprevention Trial With 4-HPR (Fenretinide) in Superficial Bladder Cancer | NCT00004154 |
| Fenretinide in Treating Patients With Leukoplakia of the Mouth | A Randomized, Double Blind, Placebo-Controlled Phase II Clinical Trial of N(4-Hydroxy-phenyl)Retinamide (Fenretinide, 4HPR) in Oral Leukoplakia | NCT00004161 |
| Fenretinide in Treating Patients With Recurrent Malignant Glioma | Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma | NCT00006080 |
| Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | A Phase II Study of Fenretinide in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT00006471 |
| 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC) | A Phase IB Randomized Translational Study of Fenretinide (4-HPR) in Combination With SCH66336, a Farnesyl Transferase Inhibitor, in Patients With Advanced or Recurrent Head and Neck Cancer | NCT00102635 |
| SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth | A Single Arm, Phase II Study to Determine the Safety and Efficacy of 4-HPRN-(4-Hydroxyphenyl) Retinamide for Treating Oral Intraepithelial Neoplasia | NCT00003223 |
| Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer | Phase II Trial Of Fenretinide (NSC-374551; IND-40, 294) In Patients With Relapsed Small Cell Lung Cancer | NCT00009971 |
| Chemotherapy in Treating Patients With Advanced Kidney Cancer | A Phase Two Study Of Fenretinide In Renal Cell Cancer | NCT00011973 |
| Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk | An Exploratory Evaluation of Fenretinide (4-HPR) as a Chemopreventive Agent for Ovarian Carcinoma | NCT00017134 |
| Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer | Phase II Trial of Fenretinide (NSC 374551) in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma | NCT00026091 |
| Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome | A Phase II Double-Blind Study of Topical Tretinoin With or Without Oral 4-HPR (Fenretinide) in Patients With the Dysplastic Nevus Syndrome | NCT00003601 |
| Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | A Phase I Trial of Fenretinide in Combination With Paclitaxel and Cisplatin | NCT00005819 |
| Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma | A Phase II Study of Fenretinide (NSC# 374551, IND# 40294) in Children With Recurrent/Resistant High Risk Neuroblastoma | NCT00053326 |
| Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme | A Phase II Evaluation With Correlative Studies Of Fenretinide (NSC 374551-4HPR) As A Single Agent In The Treatment Of Adult Patients With Recurrent Glioblastoma Multiforme | NCT00075491 |
| Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma | Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder Plus Ketoconazole Plus Vincristine in Patients With Recurrent or Resistant Neuroblastoma (IND #68,254) | NCT02163356 |
| Combination Chemotherapy in Treating Patients With Solid Tumors | A Phase I Study Of Fenretinide Combined With Paclitaxel And Cisplatin For The Treatment Of Refractory Solid Tumors | NCT00009932 |
| Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer | A Phase 2 Study Of Fenretinide In Patients With Hormone Refractory Prostate Cancer | NCT00077402 |
| Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer | A Phase II Trial of Fenretinide (4-HPR) in Biochemically Recurrent, Hormone Naive Prostate Cancer | NCT00080899 |
| Fenretinide in Treating Children With Solid Tumors | A Phase I Study of Fenretinide (NSC #374551) in Children With High Risk Solid Tumors | NCT00003191 |
| Fenretinide in Treating Patients With Solid Tumors | Phase I Evaluation of Fenretinide (NSC# 374551) | NCT00003250 |
